Mizuho reaffirmed their buy rating on shares of CytomX Therapeutics (NASDAQ:CTMX) in a report released on Monday, AnalystRatings.com reports. Mizuho currently has a $16.00 price target on the biotechnology company’s stock.
Several other analysts have also weighed in on the company. BidaskClub lowered CytomX Therapeutics from a buy rating to a hold rating in a report on Wednesday, July 24th. Zacks Investment Research raised CytomX Therapeutics from a hold rating to a strong-buy rating and set a $14.00 price objective on the stock in a report on Wednesday, July 17th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $23.00 price target (up previously from $21.00) on shares of CytomX Therapeutics in a research note on Monday, June 3rd. Nomura reaffirmed a buy rating and issued a $22.00 price target on shares of CytomX Therapeutics in a research note on Sunday, August 11th. Finally, Cowen reaffirmed a buy rating on shares of CytomX Therapeutics in a research note on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. CytomX Therapeutics currently has an average rating of Buy and an average target price of $20.22.
Shares of NASDAQ:CTMX opened at $9.07 on Monday. CytomX Therapeutics has a 1-year low of $8.78 and a 1-year high of $24.34. The business’s 50 day moving average is $10.86 and its 200-day moving average is $11.68. The company has a debt-to-equity ratio of 0.26, a current ratio of 4.66 and a quick ratio of 4.66.
A number of hedge funds have recently made changes to their positions in CTMX. Nuveen Asset Management LLC acquired a new stake in CytomX Therapeutics in the 2nd quarter valued at $8,352,000. Victory Capital Management Inc. boosted its stake in CytomX Therapeutics by 79.9% in the 1st quarter. Victory Capital Management Inc. now owns 1,655,530 shares of the biotechnology company’s stock valued at $17,797,000 after buying an additional 735,320 shares in the last quarter. First Manhattan Co. acquired a new stake in CytomX Therapeutics in the 1st quarter valued at $3,461,000. Vanguard Group Inc. boosted its stake in CytomX Therapeutics by 10.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,671,374 shares of the biotechnology company’s stock valued at $29,973,000 after buying an additional 259,355 shares in the last quarter. Finally, Spark Investment Management LLC boosted its stake in CytomX Therapeutics by 105.6% in the 1st quarter. Spark Investment Management LLC now owns 432,981 shares of the biotechnology company’s stock valued at $4,654,000 after buying an additional 222,381 shares in the last quarter. 81.62% of the stock is currently owned by institutional investors and hedge funds.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Read More: Calculate Your Return on Investment (ROI)
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.